Mode
Text Size
Log in / Sign up
N/A N=511

NAVISTAR® THERMOCOOL® SF Catheter: Observational Study

Atrial Fibrillation · Paroxysmal Arrhythmia

Enrolled (actual)
511
Serious AEs
12.4%
Results posted
Jan 2015
Primary outcome: Primary: Total Fluoroscopy Time — 26.4 minutes

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
Catheter Ablation (NAVISTAR® THERMOCOOL® SF Catheter) (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Biosense Webster, Inc.
Primary completion
Jul 2014

Outcome Measures

OutcomeResultp-value
PRIMARY
Total Fluoroscopy Time
26.4
PRIMARY
Total Procedure Time
169.8
PRIMARY
Acute Procedural Success
488
SECONDARY
Mean Number of Radiofrequency (RF) Applications
45.0
SECONDARY
Total Radiofrequency (RF) Time
57.9
SECONDARY
Fluid Volume Delivered Via Ablation Catheter
974.2
SECONDARY
Number of Patients With Repeat Ablations
74
SECONDARY
Post-procedure AF Symptoms
155
SECONDARY
Number of Subjects With Lost Work Days, Related to AF, at 12 Month Visit
20
SECONDARY
Number of Patients With Inpatient Hospital Visit(s) Related to Atrial Fibrillation
73
SECONDARY
Number of Patients With Outpatient Emergency Visits Related to Atrial Fibrillation
56
SECONDARY
Change in Atrial Fibrillation Effect on Quality of Life (AFEQT) Total Score
36.0

Summary

This is a prospective, interventional, observational, unblinded, single-arm, multicenter registry of younger and older subjects with drug refractory, recurrent, symptomatic paroxysmal atrial fibrillation.

Eligibility Criteria

Inclusion Criteria

  • Drug refractory, recurrent, symptomatic paroxysmal atrial fibrillation
  • Age 18 years or older
  • Patients must be able and willing to provide written informed consent to participate in the study

Exclusion Criteria

  • Atrial fibrillation secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause
  • Previous ablation for atrial fibrillation
  • Episodes of atrial fibrillation that last longer than 30 days and are terminated via cardioversion
  • Uncontrolled heart failure, or NYHA Class III or IV heart failure
  • Documented intra-atrial thrombus or other abnormality on pre-ablation echocardiogram
  • Contraindication to anticoagulation
  • Stroke, cardiac surgery, unstable angina, myocardial infarction or percutaneous coronary intervention within the past 3 months
  • Awaiting cardiac transplantation
  • Heart disease in which corrective surgery is anticipated within 6 months
  • Enrollment in investigational drug, biologic or device study
  • Subjects unwilling to comply with protocol or follow-up requirements
  • Patients who are pregnant
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01585961). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search